CA3165339A1 - Cd206 modulators their use and methods for preparation - Google Patents

Cd206 modulators their use and methods for preparation

Info

Publication number
CA3165339A1
CA3165339A1 CA3165339A CA3165339A CA3165339A1 CA 3165339 A1 CA3165339 A1 CA 3165339A1 CA 3165339 A CA3165339 A CA 3165339A CA 3165339 A CA3165339 A CA 3165339A CA 3165339 A1 CA3165339 A1 CA 3165339A1
Authority
CA
Canada
Prior art keywords
c6alkyl
compound
phenyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3165339A
Other languages
English (en)
French (fr)
Inventor
Raul Rolando Calvo
Bolormaa BALJINNYAM
Andres Eduardo DULCEY
Udo RUDLOFF
Mark James HENDERSON
Juan Jose Marugan
Xin Hu
Noel Terrence Southall
Rushikesh Vilas SABLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA3165339A1 publication Critical patent/CA3165339A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3165339A 2019-12-19 2020-12-16 Cd206 modulators their use and methods for preparation Pending CA3165339A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950488P 2019-12-19 2019-12-19
US62/950,488 2019-12-19
PCT/US2020/065238 WO2021126923A1 (en) 2019-12-19 2020-12-16 Cd206 modulators their use and methods for preparation

Publications (1)

Publication Number Publication Date
CA3165339A1 true CA3165339A1 (en) 2021-06-24

Family

ID=74184891

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3165339A Pending CA3165339A1 (en) 2019-12-19 2020-12-16 Cd206 modulators their use and methods for preparation

Country Status (7)

Country Link
US (1) US20230056497A1 (https=)
EP (1) EP4077297A1 (https=)
JP (2) JP7801223B2 (https=)
CN (1) CN115768757B (https=)
AU (1) AU2020404978A1 (https=)
CA (1) CA3165339A1 (https=)
WO (1) WO2021126923A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210151945A (ko) 2019-04-12 2021-12-14 립타이드 바이오사이언스, 인코포레이티드 대식세포 활성을 조정하기 위한 방법
WO2023192935A1 (en) * 2022-03-30 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the treatment for inflammation and fibrosis in retinal neovascular diseases
WO2025247783A1 (en) 2024-05-29 2025-12-04 Syngenta Crop Protection Ag Pesticidally active dihydro-benzoxazinone compounds
WO2025248032A1 (en) 2024-05-31 2025-12-04 Syngenta Crop Protection Ag Pesticidally active indazole compounds
WO2025257072A1 (en) 2024-06-14 2025-12-18 Syngenta Crop Protection Ag Pesticidally active 2-oxobenzimidazole compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
US20090209577A1 (en) 2004-08-18 2009-08-20 Pfizer Inc. Novel Triazolopyridine Compounds
BRPI0514391A (pt) * 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos de triazolopiridina para o tratamento de inflamação
ZA200704889B (en) 2004-11-23 2008-09-25 Celgene Corp JNK inhibitors for treatment of CNS injury
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
ES2642586T3 (es) * 2009-07-27 2017-11-16 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
EP2742046A1 (en) 2011-08-12 2014-06-18 F.Hoffmann-La Roche Ag PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
US10016480B2 (en) 2014-10-14 2018-07-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Peptide-based methods for treating pancreatic cancer
WO2016089977A1 (en) 2014-12-03 2016-06-09 Celgene Corporation Substituted indazole compounds, compositions thereof, and methods of treatment therewith
US10730842B2 (en) * 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
US20220340983A1 (en) * 2019-09-13 2022-10-27 Massachustts Institute Of Technology Systems and assays for identifying pu.1 inhibitors

Also Published As

Publication number Publication date
EP4077297A1 (en) 2022-10-26
US20230056497A1 (en) 2023-02-23
JP2026053706A (ja) 2026-03-25
JP2023507610A (ja) 2023-02-24
JP7801223B2 (ja) 2026-01-16
WO2021126923A1 (en) 2021-06-24
CN115768757B (zh) 2025-07-11
AU2020404978A1 (en) 2022-08-11
CN115768757A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
JP7801223B2 (ja) Ｃｄ２０６モジュレーター、その使用、および調製方法
AU2025202772A1 (en) Improved synthesis of key intermediate of KRAS G12C inhibitor compound
CN115873020A (zh) Ras抑制剂
CN114980976A (zh) 共价ras抑制剂及其用途
CN102906090B (zh) 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用
WO2024097559A1 (en) 1,5-naphthyridine derivatives as kras oncoprotein inhibitors
AU2024281092A1 (en) Ras inhibitors
JP2018104456A (ja) キナーゼ調節のための化合物と方法、及びそのための適応
WO2018045956A1 (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
JP2019515931A (ja) イソキノリン−３イル−カルボキサミドならびにその調製および使用の方法
CN103282363B (zh) 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
JP2023509155A (ja) ビフェニル系誘導体阻害剤、その調製方法及び使用
CN106488918B (zh) 三唑并嘧啶酮或三唑并吡啶酮衍生物及其用途
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
TW202334167A (zh) 作為ｅｒｂｂ２抑制劑之稠合四環喹唑啉衍生物
TW201917129A (zh) 含吡唑基的三并環類衍生物、其製備方法和應用
AU2015276699A1 (en) Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor
WO2023274280A1 (zh) 一种联苯类衍生物抑制剂的晶型及其制备方法
JP2024527044A (ja) ８－オキソ－３－アザビシクロ［３．２．１］オクタン系化合物及びその塩、並びにその調製方法及び使用
CN114269742B (zh) 作为治疗剂的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶基)嘧啶-2-胺的衍生物
TW202404591A (zh) 作為pi3k抑制劑之苯并嘧啶-4(3h)-酮
WO2025036290A1 (zh) 稠合三环类化合物、其药物组合物和用途
JP2025503099A (ja) ピリジン系誘導体、その製造方法及び使用
EP3893872A1 (en) Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
CN117886821A (zh) 含氮稠环类衍生物抑制剂、其制备方法和应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241213

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241213

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241213

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250107

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250107

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250428

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429